Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

@article{Guedj2011SecondphaseHC,
  title={Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.},
  author={J{\'e}r{\'e}mie Guedj and Alan S. Perelson},
  journal={Hepatology},
  year={2011},
  volume={53 6},
  pages={1801-8}
}
Hepatitis C virus (HCV) RNA decay during antiviral therapy is characterized by a rapid first phase, followed by a slower second phase. The current understanding of viral kinetics attributes the magnitude of the first phase of decay to treatment effectiveness, whereas the second phase of decay is attributed to the progressive loss of infected cells. Here, we analyzed data from 44 patients treated with telaprevir, a potent HCV protease inhibitor. Using a viral kinetic model that accounts for the… CONTINUE READING
53 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 53 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Combination therapy with BMS - 790052 and BMS - 650032 alone or with pegIFN / RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders [ Abstract ]

  • A Lok, D Gardiner, E Lawitz
  • HEPATOLOGY
  • 2010

Similar Papers

Loading similar papers…